Mesoblast Secures Exclusive CAR Tech License to Enhance Cell Therapy Targeting
Mesoblast secures exclusive worldwide license to CAR technology platform
Mesoblast Limited has acquired exclusive worldwide rights to a patented chimeric antigen receptor (CAR) technology platform, positioning the company to create precision-enhanced versions of its therapeutic mesenchymal stromal cell (MSC) products. The acquisition, completed through the purchase of a Mayo Clinic startup via ASX ordinary share issuance, brings engineered receptor technology designed to substantially enhance targeted homing to inflamed tissue and increase therapeutic potency.
The foundational work on the CAR technology was developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering in April 2024. As part of the exclusive licensing agreement, Mayo Clinic will provide in-kind support to advance the technology and resulting products, including GMP manufacturing activities.
This strategic acquisition builds upon Mesoblast’s existing MSC technology platforms, which already possess inherent homing capabilities and immunomodulatory properties. The aim of genetically engineering CAR constructs into the company’s MSCs is to amplify these natural characteristics, creating next-generation cell therapies with enhanced target specificity whilst augmenting existing properties of immunomodulation and tissue regeneration.
When big ASX news breaks, our subscribers know first
How CAR technology enhances cell therapy effectiveness
Chimeric antigen receptor (CAR) technology genetically engineers receptors into cells to improve their ability to find and target specific tissues. When applied to Mesoblast’s MSC products, this creates an additive technology layer that amplifies the cells’ existing capabilities rather than replacing the company’s proven platform.
The combined approach works through a three-step process:
- Mesoblast’s existing MSC products have natural tissue-homing abilities – the cells inherently migrate towards inflamed or damaged tissue
- CAR engineering adds precision targeting to inflamed tissue – genetically engineered receptors enhance the cells’ ability to locate specific inflammatory sites
- Combined effect aims to deliver greater therapeutic potency – the dual mechanism of natural homing plus engineered targeting is designed to substantially increase effectiveness
For investors, this represents R&D optionality without abandoning the company’s existing approach. The technology could potentially enhance multiple pipeline programmes whilst maintaining the foundation of Mesoblast’s first and only FDA-approved MSC product in the United States.
Immediate pipeline opportunities in inflammatory diseases
The acquisition creates two primary therapeutic development pathways identified in the announcement, targeting conditions where enhanced tissue-specific homing could deliver meaningful clinical benefits.
Inflammatory bowel disease
Mayo Clinic researchers identified CAR-MSCs with potential for enhanced targeting to inflamed bowel tissue, creating an immediate opportunity for Mesoblast to develop products with greater potency for ulcerative colitis and Crohn’s disease. This aligns directly with the company’s existing biologic-resistant inflammatory bowel disease programme, where Ryoncil is already in development.
The ability to engineer MSCs that specifically home to inflamed intestinal tissue addresses a core challenge in IBD treatment – delivering therapeutic cells precisely where inflammation occurs whilst minimising systemic exposure. This precision targeting approach could potentially improve outcomes in patients who have failed biologic therapies.
Lupus nephritis and B cell autoimmune diseases
Mesoblast plans to utilise CAR-MSC technology engineered to express CD19 on their surface to induce remission in Lupus Nephritis and other B cell autoimmune diseases. CD19 is a protein found on the surface of B cells, and engineering MSCs to express it enables targeted modulation of B cell-driven autoimmune responses.
In conditions such as Lupus Nephritis, where durable, effective and safe immunomodulation is highly desirable, the combination of MSCs’ inherent immunomodulatory properties and engineered CD19 expression represents a novel approach to achieving sustained disease control. The technology offers potential advantages over existing therapies by combining cell-based immunomodulation with precision B cell targeting.
Silviu Itescu, Chief Executive
“This innovative genetic modification technology fits well with our strategy to extend our market leadership by creating products with even greater efficacy and new target indications.”
Mayo Clinic partnership and development pathway
The strategic value of the Mayo Clinic relationship extends beyond the intellectual property acquisition, establishing a framework for ongoing collaboration and technical support. Mayo Clinic will provide in-kind assistance for advancing both the technology platform and resulting products, including critical GMP (Good Manufacturing Practice) manufacturing activities.
This ongoing support structure positions Mesoblast to accelerate development timelines whilst leveraging Mayo Clinic’s manufacturing expertise. The partnership builds upon peer-reviewed research published in Nature Biomedical Engineering (Sirpilla et al., 2024), providing scientific validation for the CAR-MSC approach.
| Element | Detail |
|---|---|
| License scope | Exclusive worldwide rights |
| Technology origin | Mayo Clinic research |
| Payment structure | ASX ordinary share issuance |
| Ongoing support | In-kind including GMP manufacturing |
Mayo Clinic maintains a financial interest in the technology through the license agreement, with revenues directed toward supporting its not-for-profit mission in patient care, education and research.
The next major ASX story will hit our subscribers first
Strategic positioning and platform expansion
The CAR platform acquisition advances Mesoblast’s broader strategy of extending market leadership through enhanced product efficacy and new target indications. The technology layer could potentially enhance multiple pipeline programmes rather than serving a single indication, representing leverage across the company’s existing portfolio.
Mesoblast’s foundation includes Ryoncil, the first and only FDA-approved MSC product in the United States, establishing regulatory precedent and commercial proof-of-concept for the company’s cell therapy approach. The existing pipeline spans multiple inflammatory and regenerative medicine applications, each potentially addressable with CAR-enhanced versions.
The company maintains a strong intellectual property position, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions, manufacturing methods and indications. This IP portfolio provides commercial protection extending through to at least 2044 in all major markets, creating a long-term competitive moat that the CAR technology acquisition now enhances.
Mesoblast’s current development programmes include:
- Ryoncil for steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients – FDA approved
- Ryoncil for SR-aGvHD in adults – in development
- Ryoncil for biologic-resistant inflammatory bowel disease – in development
- Rexlemestrocel-L for heart failure – in development
- Rexlemestrocel-L for chronic low back pain – in development
The CAR technology acquisition adds optionality to this pipeline by potentially enabling enhanced versions of existing candidates or entirely new products targeting indications where precision tissue homing could deliver differentiated clinical outcomes. For investors, this represents both a near-term catalyst through existing programmes and longer-term platform expansion potential across inflammatory disease applications.
Get Biotech Breakthroughs Before the Market Reacts
Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start getting market-moving biotech announcements the moment they break.